Co-Diagnostics reports Q1 revenue $22.7M, net income $11.7M ($0.34 EPS); no guidance given

Co-Diagnostics, Inc.

2022-Q1 EPS reported $0.34 revenue$22,699,044

Q1 revenue $22.7M, record first quarter; net income $11.7M ($0.34 diluted EPS) vs $7.9M a year ago.
Gross profit $19.4M (85.5% margin); operating income $9.8M down from $10.3M on higher R&D.
Cash, equivalents, and marketable securities $97.4M, up $7.5M from Dec 2021.
Co-Dx PCR home testing platform progressing toward FDA submission later this year.
No quarterly guidance provided due to diminished COVID-19 test sales forecasting ability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.